Aim immunotech announces positive safety data in second cohort of phase 1 clinical study investigating intranasal administration of ampligen as a potential prophylaxis or treatment for covid-19 and other respiratory viral diseases

Ocala, fla., april 27, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced that it has completed dosing of cohort 2 in a phase 1 clinical study to assess the safety, tolerability and biological activity of ampligen as an intranasal therapy, reporting no serious adverse events (sae). aim also reported no saes in cohort 1. the study will proceed with enrollment into cohort 3.
AIM Ratings Summary
AIM Quant Ranking